Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

GENERICS U.K. SALES IN 1990 WERE APPROXIMATELY $ 30 MIL., up 27% from the year before. Figures from British filings compiled by ICC information services provide a picture of the size and resources of the generics company that is challenging Glaxo's Zantac patent. Generics U.K. is an affiliate of the Canadian firm Genpharm, which made the initial filings to precipitate the patent challenge. Generics U.K. had sales of just over 17.5 mil. British pounds during its most recent full fiscal year ended April 30, 1990. This figure was up from (BRITISH POUND)13.7 mil., or $ 24.6 mil., the preceding April. Measured in pounds/sterling, the company's trading profits remained roughly constant at (BRITISH POUND)1.6 mil. in both fiscal 1989 and 1990. In U.S. dollars, they declined slightly, falling $ 2.8 mil. in FY 1989 to $ 2.6 mil. in FY 1990. Generics U.K. had total assets at the end of fiscal 1990 of approximately $ 19 mil. and just over 100 employees. Its total corporate sales are equal to about a week's worth of Zantac sales in the U.S.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts